Sepracor announces revenue growth for Q3 2008
MARLBOROUGH, Mass. Sepracor announced revenue increases of 9.6 percent, to $307.7 million, for the third quarter of 2008 in a statement Tuesday.
Reported earnings per share for the quarter were 17 cents per diluted share, compared to 34 cents per diluted share for the third quarter last year.
The company reported sales for the insomnia drug Lunesta (eszopiclone) of $154.7 million for the quarter, compared to $160.7 million for the same period last year. The inhaled asthma and chronic obstructive pulmonary disease drug Xopenex (levalbuterol hydrochloride) had sales of $77.9 million, compared to $91.6 million last year.
Medimetriks announces agreement to market treatments for impetigo
FAIRFIELD, N.J. Medimetriks Pharmaceuticals has entered into a licensing agreement with Perrigo for U.S. Marketing rights to Centany Ointment and two prescription keratolytic brands, Medimetriks announced Tuesday.
Johnson & Johnson’s OrthoNeutrogena professional division previously marketed Centany, which is used for treating impetigo caused by Straphylococcus aureas and Streptococcus pyogenes bacteria. The Food and Drug Administration approved it in 2002.
The two keratolytic brands are urea-based therapies for treating severe dry skin.
“We are happy to have a partner that brings such a record of success in the branded pharmaceutical business,” Perrigo executive vice president Sharon Kochan said in a statement. “We believe the licensed products are in good hands, given Medimetriks management’s proven abilities in building a successful business in the dermatology and podiatry markets.”
Few healthcare providers receive adequate training, tools to help patients quit smoking
NEW YORK A new study suggests that few healthcare workers have sufficient training in smoking cessation to help patients quit.
The study, presented Monday at the annual meeting of the American College of Chest Physicians in Philadelphia, found that 87 to 93 percent of healthcare providers receive less than five hours of smoking cessation training, while less than 6 percent know the governmental Agency for Healthcare Research and Quality’s guidelines for treating people with tobacco dependence.
The study surveyed 600 people working in health care, including physicians, nurse practitioners, pharmacists, social workers and students, and divided them into prescribers and non-prescribers.